T2 Biosystems (TTOO)
(Delayed Data from NSDQ)
$1.47 USD
-0.01 (-0.68%)
Updated Oct 14, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMT2 Biosystems (TTOO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.00 | $5.00 | $5.00 | 240.14% |
Price Target
Only one analyst offered a short-term price target of $5.00 for T2 Biosystems. This represents an increase of 240.14% from the last closing price of $1.47.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Hold-equivalent recommendation for T2 Biosystems. This translates to an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 3.00 a month ago based on just one recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/30/2024 | Canaccord Genuity | Kyle Mikson | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 1 |
Average Target Price | $5.00 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 82 of 252 |
Current Quarter EPS Est: | NA |